THE COMBINATION of silymarin, vitamin E, and essential phospholipids significantly improves liver function, reduces steatosis and fibrosis, and positively influences metabolic parameters in patients with MASLD over 6 months.
Metabolically-dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver condition worldwide, with rising incidence and prevalence linked to obesity, insulin resistance, and metabolic syndrome. Current treatment strategies focus on lifestyle interventions, but pharmacological approaches remain limited. Natural compounds such as silymarin, vitamin E, and essential phospholipids have individually demonstrated hepatoprotective effects, anti-inflammatory properties, and antioxidant activity, suggesting that their combination could provide synergistic benefits in managing MASLD.
This prospective clinical study enrolled 200 patients diagnosed with MASLD, with 190 completing all four scheduled visits over 6 months. Patients received a formula combining silymarin, vitamin E, and essential phospholipids. At baseline (visit 0) and follow-up visits, liver function tests, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and alkaline phosphatase (ALP), were monitored, along with lipid profiles, blood glucose levels, and non-invasive assessments of hepatic steatosis and fibrosis. Over the 6-month period, statistically significant improvements were observed across multiple parameters: ALT, AST, GGT, ALP, triglycerides, total cholesterol, and blood glucose levels all decreased (p<0.0001), while fibrosis scores also showed a significant reduction from baseline to the final visit (p=0.002). Steatosis grades improved notably, suggesting that the combined therapy had a meaningful impact on liver fat accumulation even within a relatively short treatment window.
These findings support the therapeutic potential of combining silymarin, vitamin E, and essential phospholipids in MASLD management. The treatment was well tolerated, with no adverse effects reported, highlighting its suitability for clinical practice as a safe, non-invasive intervention.
Reference
Gheonea DI et al. Therapeutic efficacy of silymarin, vitamin E, and essential phospholipid combination therapy on hepatic steatosis, fibrosis, and metabolic parameters in MASLD patients: a prospective clinical study. Int J Mol Sci. 2025;26(12):5427.
